{"filings":[{"id":2337756,"accession_number":"0001757073-26-000074","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-08-19T12:38:34+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Envista CEO Paul Keel named Chairman; gets $10M equity award, salary bump","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Keel appointed Chairman of Board effective Aug 19, 2026; Scott Huennekens becomes Lead Independent Director.","Keel base salary raised from $1.1M to $1.3M annually, effective Aug 24, 2026.","Keel receives one-time equity award of $10M: $5M RSUs vesting over 4 years, $5M PSUs tied to 4-year TSR vs S&P 400 Health Care.","CFO Eric Hammes receives $1.5M PSU award with same TSR performance condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2079082,"accession_number":"0001757073-26-000063","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-08-05T20:12:56+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 core sales +5%, adj. EPS $0.41 (+58% YoY); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $731M, core sales growth 5.0% YoY; GAAP net income $54M vs $26M in Q2 2025.","Adjusted diluted EPS $0.41 (+58% YoY); adjusted EBITDA $108M (+28% YoY), margin 14.7% (+230 bps).","Specialty Products & Technologies core sales +3.1%; Equipment & Consumables core sales +8.5%.","FY 2026 guidance raised: core sales growth 3.5%-4.5% (prev. 2%-4%), adj. EPS $1.50-$1.55 (prev. $1.35-$1.45).","Repurchased 2.4M shares for ~$59M; $283M remaining under stock repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":835556,"accession_number":"0001757073-26-000051","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-06-03T20:54:52+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envista CAO Faez Kaabi to retire Aug 6, 2026; Coree Thomas appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Faez Kaabi notified resignation as CAO and principal accounting officer effective Aug 6, 2026, due to retirement.","No disagreement with the company over financial disclosures or accounting matters cited for departure.","Kaabi will remain in role through transition; Coree Thomas appointed VP and CAO effective Aug 6, 2026.","Thomas, 48, has served as VP Global Controller since Feb 2023; prior roles at CBRE, Edwards Lifesciences, Exelon, KPMG.","No family relationships or related party transactions disclosed with Thomas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582516,"accession_number":"0001757073-26-000043","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-05-21T20:24:18+00:00","items":["5.07","9.01"],"status":"ready","headline":"Envista Holdings 2026 annual meeting: all 8 directors elected; EY ratified; say-on-pay approved; annual vote adopted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all eight director nominees: votes for ranged from 145,760,570 to 149,459,395.","Ratified Ernst & Young as auditor for 2026: 152,689,635 for, 913,161 against, 65,730 abstain.","Approved say-on-pay with 144,475,242 votes for, 5,144,798 against, 73,034 abstain.","Advisory vote on frequency of future say-on-pay: 139,798,463 for one year, 9,840,878 for three years; company adopts annual vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95226,"accession_number":"0001757073-26-000040","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 2026: core sales +9.5%, adjusted EPS $0.36 (+50% YoY), new $300M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $706M, core sales growth 9.5% YoY; Specialty Products +8.4%, Equipment & Consumables +11.5%.","GAAP diluted EPS $0.23; adjusted diluted EPS $0.36 (+50% YoY).","Adjusted EBITDA $99M (+25% YoY), margin 14.0% (+120 bps).","Operating cash flow -$3M, free cash flow -$16M vs -$5M prior year.","Board authorized $300M share repurchase through Dec 2029; FY2026 guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":705500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108131,"accession_number":"0001757073-26-000005","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 2025: core revenue +10.8%, adj. EPS $0.38 (+58% YoY); FY 2026 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $751M; core sales +10.8% YoY; GAAP EPS $0.20; adjusted EPS $0.38 (+58%).","FY 2025 core sales +6.5%; adjusted EBITDA $372M (+26% YoY); adjusted EPS $1.19 (+63%).","FY 2026 guidance: core sales growth 2-4%, adj. EBITDA growth 7-13%, adj. EPS $1.35-$1.45.","Repurchased 9.2M shares for $166M in FY 2025; ~$84M repurchase capacity remaining.","All major businesses/geographies positive; Spark achieved positive operating margin in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2719500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124547,"accession_number":"0001757073-25-000055","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q3 core sales up 9.4%; adj EPS $0.32 vs $0.12 YoY; raises FY core sales growth outlook to ~4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $670M, core sales growth 9.4% YoY; all major businesses positive growth.","GAAP EPS ($0.18) on $30M tax charge; adjusted EPS $0.32 (+167% YoY); adjusted EBITDA $97M (+77%), margin 14.5%.","Spark aligners achieved positive operating margin; share repurchases of 2.1M shares for $41M in Q3.","Updated FY2025 guidance: core sales growth ~4% (prior 3-4%), adj EPS $1.10-$1.15 (prior $1.05-$1.15), adj EBITDA margin ~14%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":1968900000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124546,"accession_number":"0001757073-25-000053","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista releases 2024 Sustainability Report; $1.9M donated, safety incident rate down 13%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Donated $1.9M in goods/services via Envista Smile Project to expand oral care access for underserved communities.","Completed inaugural Scope 3 GHG emissions inventory to better manage environmental footprint.","Safety incident rate reduced by 13% year-over-year.","CEO Paul Keel highlighted progress across ESG focus areas including ethics, community, and environment.","Report available on company website; stakeholder feedback invited via sustainability@envistaco.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141232,"accession_number":"0001757073-25-000050","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Barbara B. Hulit resigns from Envista board effective Sept 26, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara B. Hulit submitted her resignation from the Board on September 15, 2025.","Resignation is effective September 26, 2025; she cited pursuit of another opportunity.","Her decision was not the result of any disagreement with the company on operations, policies, or practices.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141231,"accession_number":"0001757073-25-000042","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).","Core sales growth 5.6% YoY across all businesses and geographies, including Nobel Biocare in North America.","FY2025 guidance raised: core sales growth 3-4% (prior 1-3%), adjusted EPS $1.05-$1.15 (prior $0.95-$1.05).","Repurchased 4.8M shares for ~$82M in Q2; $150M remaining under buyback program.","YTD operating cash flow $89M, free cash flow $71M, down from $133M and $116M in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1299000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141230,"accession_number":"0001757073-25-000036","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envista appoints Stryker executive J. Andrew Pierce to Board, adds Audit Committee role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Andrew Pierce elected to Board effective July 14, 2025, expanding Board from 8 to 9 members.","Pierce is Group President, MedSurg & Neurotechnology at Stryker since 2019; 29-year Stryker veteran.","Pierce joins Audit Committee; Board committee composition updated accordingly.","He will receive standard non-employee director compensation, pro-rated for FY2025, plus equity awards and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159030,"accession_number":"0001628280-25-031044","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Envist stockholders approve all four proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with >99% support for most.","Ratification of Ernst & Young as auditor approved with 99.8% votes in favor.","Advisory vote on executive compensation approved with ~94% support.","Amendment to Omnibus Incentive Plan to add 6.425M shares approved with ~94% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159029,"accession_number":"0001757073-25-000026","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 sales $617M, adj. EPS $0.24, maintains 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $617M, core sales +0.2% YoY; net income $18M, adjusted net income $42M.","EPS $0.10, adjusted EPS $0.24 (ahead of expectations); adj. EBITDA $79M (12.8% margin).","Operating cash flow $0M, free cash flow ($5)M vs $29M last year; repurchased 1.1M shares for $19M.","Maintains FY2025 outlook: core sales growth 1-3%, adj. EPS $0.95-$1.05, adj. EBITDA margin ≈14%.","Growth in Consumables, Nobel Biocare, Spark; soft Diagnostics; China ortho down due to VBP preparations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":616900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177472,"accession_number":"0001757073-25-000006","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envista authorizes $250M share repurchase program through Dec 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $250 million in common stock.","Program runs from Feb 5, 2025 to Dec 31, 2026.","Repurchases may be via open market, privately negotiated, accelerated or 10b5-1 plans.","No other material events reported in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177471,"accession_number":"0001757073-25-000005","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.","Full-year 2024 net loss $1.12B (incl. impairment), adjusted net income $127M vs $269M in 2023.","Free cash flow $124M in Q4, up 24% YoY; operating cash flow $132M, up 30%.","Implants improved with growth in Nobel Biocare, Implant Direct, Alpha-Bio; Spark aligners gained share and gross margin.","FY2025 guidance: core sales growth 1-3%, adjusted EBITDA margin ~14%, adjusted EPS $0.95-$1.05."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2510600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194201,"accession_number":"0001757073-24-000080","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista releases 2023 Sustainability Report with 26% reduction in Scope 1 GHG emissions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Absolute Scope 1 GHG emissions decreased 26% year-over-year; total (Scope 1+2) intensity down 3.5%.","Donated nearly $1.3 million to oral health non-profits through the Envista Smile Project.","Achieved 99% gender pay equity and 99% ethnic pay equity in the U.S.","Invested in Kaizen projects to improve sustainability and operational efficiency at multiple facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194200,"accession_number":"0001757073-24-000077","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q3: net income $8.2M ($0.05 EPS), core sales down 5.3%, adj EBITDA $54.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $8.2M ($0.05 diluted EPS) vs $21.5M ($0.12) in Q3 2023.","Adjusted net income $21.1M ($0.12 diluted EPS) vs $75.5M ($0.43) in Q3 2023.","Adjusted EBITDA $54.9M compared to $123.5M in prior-year quarter.","Core sales declined 5.3% YoY; reported sales $601.0M.","Full-year 2024 guidance reaffirmed: core sales -1% to -4%, adjusted EBITDA margin 10%-12%."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1857700000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210526,"accession_number":"0001757073-24-000065","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 net loss $1.15B on $1.15B goodwill impairment; guides FY core sales down 1-4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1,151.6M ($6.69 per share) includes $1,153.8M non-cash goodwill and intangible impairment.","Adjusted net income $18.5M ($0.11 adj EPS) vs $76.2M ($0.43) in Q2 2023.","Reported sales $633.1M; core sales declined 3.2% YoY; adjusted EBITDA fell to $63.0M from $126.2M.","FY 2024 guidance: core sales decline 1%-4%, adj EBITDA margin 10%-12%; expects Q3 further decline, Q4 return to growth.","CEO Paul Keel cited repositioning actions including new permanent CFO and Presidents for two largest businesses."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1256700000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210525,"accession_number":"0001757073-24-000063","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista appoints Eric Hammes as CFO, Stefan Nilsson and Veronica Acurio to lead Nobel Biocare and Ormco","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Hammes appointed CFO effective August 8, 2024; interim CFO Stephen Keller returns to lead investor relations.","Hammes compensation: base salary $575k, target bonus 75% of salary, LTI $1.2M, one-time cash $1.02M, RSUs $1.2M.","Stefan Nilsson named President of Nobel Biocare, effective July 15; previously CEO of Colosseum Dental Group.","Veronica Acurio named President of Orthodontics (Ormco), effective August 2; formerly President of 3M Medical Solutions Division.","CEO Paul Keel cites relevant dental and healthcare experience; appointments expand leadership team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228854,"accession_number":"0001757073-24-000059","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envista's SVP & President of Orthodontics Eric Conley steps down effective June 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Conley notified Envista on May 27, 2024, that he will step down as SVP and President, Orthodontics.","Departure effective June 3, 2024; Conley is leaving to pursue another opportunity.","Decision not the result of any disagreement with Envista; no replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228853,"accession_number":"0001757073-24-000056","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Envista annual meeting results: officer exculpation approved, Paul Keel elected director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment to exculpate officers approved: 130.7M for, 27.6M against, effective May 21, 2024.","Paul Keel elected as additional director with 154.3M votes for (98.5% of votes cast).","All incumbent directors re-elected; Daniel Raskas received 91.8M for vs 66.6M withheld, lowest support.","Advisory say-on-pay approved: 148.8M for, 9.5M against.","Ratification of Ernst & Young as auditor passed with 160.9M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228852,"accession_number":"0001757073-24-000038","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 net income $23.6M, adjusted EPS $0.26 (down 32% YoY); Paul Keel appointed CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $623.6M, core sales up 0.4% YoY.","Net income $23.6M ($0.14 diluted EPS); adjusted net income $45.8M ($0.26 diluted EPS), down from $0.38 in Q1 2023.","Adjusted EBITDA $87.2M, down from $114.0M in Q1 2023.","Spark business grew double digits with expanding margins; value implant business returned to growth, consumables stabilized.","Paul Keel appointed CEO effective May 1, 2024; Amir Aghdaei remains Senior Advisor and shareholder."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":623600000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228851,"accession_number":"0001757073-24-000036","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista appoints Paul Keel as CEO effective May 1, 2024; succeeds Amir Aghdaei","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Keel, former CEO of Smiths Group plc, named President & CEO and board member effective May 1, 2024.","Base salary of $1.1M, target annual cash bonus of 150% of salary (max 300%), and initial equity awards valued at $6.5M for FY2024 plus $11M replacement equity.","Relocation reimbursement up to $650k (with gross-up), subject to clawback if employment terminated within 12 months for cause.","Outgoing CEO Amir Aghdaei to resign from board on same date and will serve as senior advisor during transition.","Employment agreement includes non-compete, non-solicitation, non-disparagement, and perpetual non-disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247496,"accession_number":"0001757073-24-000031","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista director Barbara Hulit terminates consulting agreement, effective Apr 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement with director Barbara Hulit signed Jan 2, 2024, for 180-day term.","Hulit gave termination notice on Mar 26; arrangement ends Apr 30, 2024.","Compensation: $124,800/month cash plus $1.5M in RSUs over six months.","No reason provided for early termination; Hulit continues as Envista director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247495,"accession_number":"0001757073-24-000022","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista announces planned CEO succession; Aghdaei to step down once successor appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Amir Aghdaei to step down upon appointment of successor; board formed search committee for external candidates.","Transition agreement signed Feb 22, 2024; Aghdaei eligible for target bonuses for FY2023 and FY2024 based on actual performance.","Aghdaei to receive FY2024 equity award of $5.5M and consulting fee of $1.5M over 18 months post-transition.","Aghdaei remains President/CEO until successor appointed; process expected to complete in 2024.","Under transition agreement, Aghdaei forfeits eligibility for severance under the existing severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247494,"accession_number":"0001757073-24-000011","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 net loss $217.4M on $258.3M impairment; adjusted EPS $0.29; guides FY2024 margin 16-17%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $645.6M, core sales down 2.0% YoY; net loss of $1.27 diluted EPS includes $258.3M goodwill/intangibles impairment.","Adjusted net income $49.7M ($0.29 EPS) vs $91.9M ($0.52 EPS) in Q4 2022; adjusted EBITDA $100.5M vs $138.3M.","FY2023 free cash flow $223.6M, up >$100M vs 2022; orthodontic Spark Aligner grew over 50% for the year.","FY2024 guidance: core sales low-single-digit growth; adjusted EBITDA margin of 16%-17%, down from 18.1% in FY2023.","CEO cites volatile macro, plans to improve Spark profitability and accelerate North American implant business in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":2566500000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264957,"accession_number":"0001757073-23-000078","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista names three new executives; Nobel Biocare president exits Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrik Eriksson, SVP and President of Nobel Biocare, departs effective Dec 31, 2023.","Robert Befidi appointed President, Diagnostics; previously led division at 3M.","Suraj Satpathy appointed Chief Human Resources Officer; formerly SVP HR at Cepheid.","Andrew Chen appointed Chief Information Officer; previously CIO at Kite Pharma.","External search for permanent CFO is underway; CEO Aghdaei directly overseeing Nobel Biocare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264956,"accession_number":"0001757073-23-000075","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista releases 2022 Sustainability Report; highlights 20% GHG reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scope 1 and 2 GHG emissions down 20% absolute, 22% intensity YoY.","Invested ~$650,000 via the Envista Smile Project for oral health nonprofits.","Achieved 99% gender pay equity and 99% ethnic pay equity in the U.S.","Established cross-functional Sustainability Council to improve ESG across value chain.","Improved employee health and safety outcomes through EHS system investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264955,"accession_number":"0001757073-23-000070","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q3 adj EPS $0.43, revises FY core sales outlook to slightly down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $631.3M, core sales up 0.8% YoY.","Adjusted diluted EPS $0.43 (vs $0.47 in Q3 2022); GAAP EPS $0.12.","Adjusted EBITDA $123.5M, margin 19.6% (vs $127.6M in Q3 2022).","Guidance: FY 2023 core sales now expected down slightly; adj. EBITDA margin 18%-19%.","Specialty segment grew low-single digit (Spark outperformed); Equip & Consumables declined low-single digit."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1920900000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282145,"accession_number":"0001757073-23-000063","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["2.03","1.01","9.01"],"status":"ready","headline":"Envista refinances with $530M USD and €350M EUR term loans; revolver $750M thru Aug 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second amended credit agreement signed Aug 31, 2023; matures Aug 31, 2028 with springing maturity tied to convertible notes.","Incurred USD term loan $530M and EUR term loan €350M; revolving commitments $750M.","Proceeds used to refinance existing credit agreement and for general corporate purposes.","Spread adjustment for Term SOFR loans set at flat 10 bps; other interest rates unchanged.","Approximately $4.7M in fees paid in connection with the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282144,"accession_number":"0001193125-23-210713","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Envista issues $500M 1.75% convertible notes due 2028, exchanges $401M existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500.25M in 1.75% Convertible Senior Notes due August 2028; initial conversion rate 21.5942 shares per $1,000 principal (~$46.31/share).","Exchanged $401.2M of existing 2.375% Convertible Notes due 2025 for $403M cash plus 8.4M common shares in privately negotiated deals.","New notes are senior unsecured; redemption option after Aug 2026 if stock exceeds 130% of conversion price.","Overall refinancing reduces interest cost from 2.375% to 1.75% and extends maturity from 2025 to 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282143,"accession_number":"0001757073-23-000062","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envista prices $435M 1.75% convertible notes due 2028; concurrent exchange of 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$435M principal of 1.75% convertible notes due 2028 priced; underwriters option for additional $65.25M.","Net proceeds ~$422.6M; ~$403M used to exchange ~$401.2M principal of existing 2.375% 2025 notes.","Initial conversion price ~$46.31/share, a 32.5% premium over $34.95 closing price on Aug 7.","Notes rated Baa3 by Moody's; settlement expected Aug 10, 2023; mature Aug 15, 2028.","Concurrent exchange of 2025 notes for ~$403M cash and ~8.4M shares of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282142,"accession_number":"0001757073-23-000061","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envista announces $435M convertible notes offering, concurrent exchange of 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$435M principal of Convertible Senior Notes due 2028; initial purchasers option for additional $65.25M.","Notes mature August 15, 2028; interest rate, conversion rate set at pricing.","Proceeds to pay cash portion of concurrent exchange of 2.375% 2025 Notes and for general corporate purposes.","Concurrent exchange of outstanding 2025 Notes for cash and common stock with limited holders.","Expects to terminate portion of Existing Capped Call Transactions; hedge unwind may affect stock price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282141,"accession_number":"0001757073-23-000059","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 revenue up 2.6% to $662.4M; adjusted EPS $0.43 vs $0.48 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $662.4M (+2.6% YoY); core sales +2.1%.","GAAP net income $51.9M ($0.29 diluted EPS).","Adjusted net income $76.2M ($0.43 diluted EPS) vs $86.0M ($0.48) in Q2 2022.","Adjusted EBITDA $126.2M (19.1% margin) vs $126.9M in prior year.","Equipment & Consumables returned to growth; Spark strong, offsetting Russia sanctions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":1289600000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282140,"accession_number":"0001757073-23-000058","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Envista CFO Howard Yu to step down Sept 22; interim CFO and CAO appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Howard Yu resigns as SVP & CFO effective Sept 22, 2023, to join another company; no disagreement with Envista.","Stephen Keller, VP Investor Relations, named interim principal financial officer upon Yu's departure.","Faez Kaabi, VP Corporate Controller, appointed VP & Chief Accounting Officer, effective Sept 22.","Envista will report Q2 2023 results on Aug 2, 2023, and expects to reaffirm full-year 2023 guidance and long-term outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301256,"accession_number":"0001757073-23-000055","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Envista SVP Kyrillos departs; severance package totals $1.096M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Claude Kyrillos, SVP & President of Diagnostics and Digital Solutions, left effective June 30, 2023, as previously announced.","Severance includes $892,500 (12 months base salary plus annual bonus target) paid over 12 months.","Also receives pro-rata annual bonus of $183,750 and lump-sum health coverage contribution of $19,313.","Separation agreement includes general release and continued confidentiality, non-compete, and non-solicitation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301255,"accession_number":"0001757073-23-000051","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"NVST annual meeting results: directors elected, EY ratified, say-on-pay approved; bylaws amended","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected directors: Aghdaei, Gallahue, Hulit, Jain, Raskas (lowest votes for Raskas: 88M for vs 67M withheld).","Ratification of EY as auditor: 157.4M for, 62.9k against, 108.7k abstain.","Advisory vote on exec comp approved: 146.3M for, 8.8M against, 82.7k abstain.","Bylaws amended to update Delaware law provisions and advance notice rules under Rule 14a-19."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301254,"accession_number":"0001757073-23-000040","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 sales down 0.7% to $627.2M; adjusted EPS $0.38 vs $0.47 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $627.2M (-0.7%); core sales declined 2.4% YoY.","GAAP net income $43.8M ($0.25 diluted EPS); adjusted net income $67.8M ($0.38 diluted EPS).","Adjusted EBITDA $114.0M vs $124.6M in Q1 2022 (down 8.5%).","CEO cites China/Russia headwinds and weaker large capital equipment; expects growth to accelerate in 2023.","No GAAP forward guidance provided; company does not reconcile non-GAAP measures."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":627200000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301253,"accession_number":"0001757073-23-000037","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Envista SVP and President of Diagnostics & Digital Solutions to depart June 30, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Claude Kyrillos, SVP and President of Diagnostics and Digital Solutions, mutually agreed to terminate employment effective June 30, 2023.","No successor or interim replacement named in the filing.","Departure covers a key business segment (Diagnostics and Digital Solutions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321108,"accession_number":"0001757073-23-000007","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 adjusted EPS $0.52 beats $0.46; guides 2023 low-single-digit core growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $660.8M (+1.4% reported; +2.3% core).","GAAP net income $73.5M ($0.42 diluted EPS); adjusted net income $91.9M ($0.52) vs $81.1M ($0.46) a year ago.","Q4 adjusted EBITDA $138.3M vs $120.7M in Q4 2021; full-year adjusted EBITDA margin 20.1%.","2023 guidance: core sales growth low-single digits; adjusted EBITDA margin >20%.","CEO cites strong execution, EBS culture, and commitment to digitizing dental care."],"consensus_eps_estimate":null,"consensus_eps_actual":1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":2569100000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339217,"accession_number":"0001757073-22-000090","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista beats Q3 estimates; core sales up 4.9%, adjusted EPS $0.47 vs $0.45 YoY; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported sales $631.1M, core growth 4.9% YoY.","GAAP diluted EPS $0.28; adjusted EPS $0.47 vs $0.45 in prior year.","Adjusted EBITDA $127.6M vs $119.1M YoY; margin 20.2%.","FY 2022 guidance reaffirmed: mid-single digit core sales growth, 20% adjusted EBITDA margin.","CEO cites strong Spark Clear Aligners and premium implant growth, digital expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1908300000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339216,"accession_number":"0001757073-22-000089","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista releases 2021 Sustainability Report highlighting ESG progress","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Achieved 99% gender pay equity and 99% ethnic pay equity in the U.S.","Aligned with TCFD recommendations; identified climate risks and opportunities.","Conducted first employee Engagement Survey to set improvement baseline.","Launched Envista Smile Project philanthropic foundation for underserved communities.","Began phasing out classified Board of Directors to improve stakeholder responsiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356593,"accession_number":"0001757073-22-000086","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 sales $645.8M (+1.3%), core sales +4.0%; adj EPS $0.48; guidance revised to mid-single digits growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $645.8M (+1.3% YoY), core sales growth 4.0%; net income $44.5M ($0.25 diluted EPS).","Adjusted net income $86.0M, adjusted EPS $0.48 (vs $0.46 in Q2 2021); adjusted EBITDA $126.9M, margin 19.7%.","FY 2022 guidance: core sales growth revised to mid-single digits; maintains adjusted EBITDA margin target of 20%.","Closed acquisitions of Carestream Dental's IOS business (Q2) and Osteogenics Regenerative Solutions (July).","Cites headwinds: supply chain disruptions, inflation, geopolitical uncertainties, China COVID lockdown."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1277200000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375030,"accession_number":"0001757073-22-000065","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Envista stockholders elect three directors, ratify auditor, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Amir Aghdaei, Vivek Jain, Daniel A. Raskas elected with >150M votes each.","Ernst & Young ratified as auditor: 155,565,988 for, 19,637 against.","Advisory say-on-pay approved: 146,572,618 for, 6,221,238 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375029,"accession_number":"0001757073-22-000064","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista to acquire Osteogenics Biomedical for ~$30M annual sales; closes Q3","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Definitive agreement to acquire Osteogenics Biomedical, Allotech, OBI Biologics (Cytoplast brand).","Osteogenics has ~$30M annual sales; leader in regenerative solutions for dental bone grafting.","Transaction subject to customary regulatory approvals; expected close in Q3 2022.","No financing condition or shareholder vote required; funded from existing resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375028,"accession_number":"0001757073-22-000060","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 sales $631.4M, core growth 5.4%, completes IOS acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $631.4M (+3.1% as-reported, +5.4% core growth YoY).","GAAP diluted EPS $0.39; adjusted diluted EPS $0.47 vs $0.49 in Q1 2021.","Adjusted EBITDA $124.6M (19.7% margin) vs $132.3M prior year.","Completed acquisition of Carestream Dental's intraoral scanner business; expects $35-45M IOS sales in 2022.","FY2022 guidance: core sales growth 6-8%, adj. EBITDA margin >20%; Q2 mid-single digit core growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":631400000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375027,"accession_number":"0001757073-22-000057","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Envista closes $582.5M acquisition of Carestream Dental's intraoral scanner business, rebrands as DEXIS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration of $582.5 million for certain assets, liabilities, and equity of Carestream subsidiaries.","Acquired business will be rebranded as DEXIS and operate within Envista Equipment and Consumables Segment.","Inclusion of intraoral scanners and software; Carestream's Imaging Equipment and Practice Management businesses are not part of the deal.","CEO Amir Aghdaei highlights digital workflow benefits for implants, prosthetics, and aligners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393435,"accession_number":"0001757073-22-000053","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Envista CAO resigns; CFO assumes accounting officer role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kari-Lyn Moore resigns as Chief Accounting Officer effective April 22, 2022.","Resignation is for a new professional opportunity, not related to any disagreement on financial disclosures or accounting.","CFO Howard H. Yu will serve as principal accounting officer in addition to his CFO and principal financial officer duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393434,"accession_number":"0001757073-22-000005","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 sales up 5.8% to $651.8M; guides FY22 core growth 6-8%, adj EBITDA margin >20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $42.5M ($0.24 diluted EPS); adjusted EPS $0.46 vs $0.43 in Q4 2020.","Full-year 2021 core sales growth 29%; Q4 core sales growth 6.6% on $651.8M revenue.","2022 guidance: core growth 6-8%, adjusted EBITDA margin >20%, barring significant COVID disruptions.","Pending acquisition of Carestream Dental's IOS business expected to close in Q2 2022; excluded from guidance.","Completed sale of KaVo Treatment Unit and Instrument business on Dec 31, 2021; results reflect continuing operations."],"consensus_eps_estimate":null,"consensus_eps_actual":1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2508900000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393433,"accession_number":"0001757073-22-000002","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Envista closes divestiture of KaVo Treatment Unit & Instrument business for $383M total proceeds","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $317.3M cash at closing; expects total gross proceeds of $383M including $30M earnout and $36.2M adjustments.","Sale includes deferred local closings in Russia, China, and Brazil until asset transfer entities are formed.","Proceeds will fund strategic acquisitions and internal investments in consumables and digital workflow portfolio.","KaVo Imaging business remains with Envista as part of the Equipment & Consumables segment.","Divestiture originally announced September 7, 2021; closed December 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-03T23:59:59+00:00|393433"}